AGC Biologics Revenue and Competitors

Seattle, WA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AGC Biologics's estimated annual revenue is currently $447.8M per year.(i)
  • AGC Biologics's estimated revenue per employee is $155,000

Employee Data

  • AGC Biologics has 2889 Employees.(i)
  • AGC Biologics grew their employee count by 16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6200%N/AN/A
#2
$1.1M7-36%N/AN/A
#3
$4.8M3119%N/AN/A
#4
$1.3M17-23%N/AN/A
#5
$31.6M1633%$30.2MN/A
#6
$1.9M120%N/AN/A
#7
$4.2M27-16%N/AN/A
#8
$2.5M16-27%N/AN/A
#9
$0.9M60%N/AN/A
#10
$2.8M180%N/AN/A
Add Company

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan. AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, both mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression including our proprietary CHEF1® Expression System for mammalian production. Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time. Visit www.agcbio.com to learn why AGC Biologics is a World Leader in process development and contract manufacturing.

keywords:N/A

N/A

Total Funding

2889

Number of Employees

$447.8M

Revenue (est)

16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AGC Biologics News

2022-04-20 - Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer

... Lonza, Juno/Celgene, and most recently AGC Biologics, ... has a strong pre-clinical pipeline with multiple biologic and next generation...

2022-04-19 - Global GMP Grade Plasmid DNA Market Competitive Analysis ...

Cobra Biologics; VGXI; AGC Biologics; Waisman Biomanufacturing; PlasmidFactory; Nature Technology Corporation (NTC); Gedeon Richter; Eurogentec...

2022-03-30 - Allergy Therapeutics Selects AGC Biologics to Manufacture ...

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to...

2021-09-17 - Chi­nese biotech Ever­est signs $550M+ li­cens­ing deal for BTK in­hibitors on heels of Covid-19 pact

AGC Biologics is significantly expanding a German site focusing on cell and gene therapies. The Seattle company will add another cGMP manufacturing line at its Heidelberg facilities, which already feature 100-liter and 1,000-liter manufacturing capacities for microbial protein and cell and gene ...

2021-03-02 - AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

SEATTLE, March 2, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1546.3M334722%N/A
#2
$1750M347917%$1.7B
#3
$1750M407224%N/A